Stockscreener 앱 받기
17.87
1.25%
0.22
시장 영업 전:
17.86
-0.01
-0.06%
전일 마감가:
$17.65
열려 있는:
$17.83
하루 거래량:
451.89K
Relative Volume:
3.76
시가총액:
$843.00M
수익:
-
순이익/손실:
-
주가수익비율:
-11.93
EPS:
-1.4981
순현금흐름:
-
1주 성능:
+4.56%
1개월 성능:
+1.42%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$17.33
$18.25
1주일 범위
$16.00
$18.38
52주 변동 폭
$16.00
$18.60
Odyssey Therapeutics Inc Stock (ODTX) Company Profile
Compare ODTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ODTX
Odyssey Therapeutics Inc
|
17.87 | 832.62M | 0 | 0 | 0 | -1.4981 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Odyssey Therapeutics Inc 주식(ODTX)의 최신 뉴스
FMR LLC's Strategic Acquisition of Odyssey Therapeutics Inc Shar - GuruFocus
IPO Tracker 2026: Kardigan stitches up $369M IPO plan - BioSpace
Anthony W. Opipari Net Worth (2026) - GuruFocus
Aranicki Ksenija Pavletic Net Worth (2026) - GuruFocus
Todd Collin M Net Worth (2026) - GuruFocus
Natalie Dales Net Worth (2026) - GuruFocus
Gary D Glick Net Worth (2026) - GuruFocus
FMR LLC discloses 4.58M-share stake in Odyssey Therapeutics (ODTX) - Stock Titan
Odyssey Therapeutics (ODTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
ODTX Technical Analysis & ETF Price Forecast - Intellectia AI
Latest ODTX ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
ODTX Initiates Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
ODTX Initiates Coverage by JP Morgan -- Price Target Set at $26 - GuruFocus
ODTX Initiated Coverage by Cantor Fitzgerald -- Rated Overweight - GuruFocus
ODTX Initiates Coverage by Wedbush -- Price Target Announced at $30 - GuruFocus
Odyssey Therapeutics (ODTX) Rated Outperform with $30 Target - GuruFocus
ODTX Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
This Oppenheimer Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
A Quick Look at Today's Ratings for Odyssey Therapeutics(ODTX.US), With a Forecast Between $16.96 to $40 - Moomoo
Wedbush Initiates Odyssey Therapeutics at Outperform With $30 Price Target - marketscreener.com
Oppenheimer initiates Odyssey Therapeutics stock with outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Odyssey Therapeutics stock with outperform rating - Investing.com
TD Cowen initiates Odyssey Therapeutics stock at Buy on drug pipeline - Investing.com
Cantor Fitzgerald Initiates Odyssey Therapeutics at Overweight - marketscreener.com
Oppenheimer Initiates Odyssey Therapeutics at Outperform With $40 Price Target - marketscreener.com
TD Cowen Initiates Odyssey Therapeutics at Buy - marketscreener.com
JPMorgan Initiates Odyssey Therapeutics at Overweight With $26 Price Target - marketscreener.com
JPMorgan initiates Odyssey Therapeutics stock rating at Overweight By Investing.com - Investing.com India
JPMorgan initiates Odyssey Therapeutics stock rating at Overweight - Investing.com
Odyssey Therapeutics (ODTX) Stock Analysis Report | Financials & Insights - Benzinga
Health stocks Odyssey, Mobia disappoint on first day of trading - MSN
ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:17.500|Chg%:-0.24 - TradingKey
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ODTX Technical Analysis | Trend, Signals & Chart Patterns | ODYSSEY THERAPEUTICS INC (NASDAQ:ODTX) - ChartMill
Odyssey Therapeutics hits $900M valuation in Nasdaq debut, stock climbs 13% before diving lower - MSN
ODTX SEC FilingsODYSSEY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Simeon George Discloses Investment at Odyssey Therapeutics with 8.0% Stake - TradingView
SR One funds disclose 8% Odyssey Therapeutics (ODTX) stake after IPO - Stock Titan
TPG funds take 7.8% Odyssey Therapeutics (ODTX) stake via $25M share purchase - Stock Titan
Odyssey Therapeutics (ODTX) Stock Forecast and Price Target 2026 - MarketBeat
Odyssey Therapeutics (ODTX) Stock Chart and Price History 2026 - MarketBeat
Dimension Management Discloses Investment at Odyssey Therapeutics with 7.1% Stake - TradingView
Jeito II S.L.P. Discloses Investment in Odyssey Therapeutics with 7.8% Stake - TradingView
What is the current Price Target and Forecast for Odyssey Therapeutics, Inc. (ODTX) - Zacks Investment Research
Immunology drug developer Odyssey seeks US IPO again - MSN
Odyssey Therapeutics Inc (ODTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Odyssey Therapeutics Inc 주식 (ODTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dimension Capital II, L.P. | Director |
May 08 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
1,831,383 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Sale |
18.00 |
1,780 |
32,040 |
440,981 |
| LEIDEN JEFFREY M | Director |
May 08 '26 |
Buy |
20.00 |
5,000 |
100,000 |
270,198 |
| Haas Jason | Chief Financial Officer |
May 08 '26 |
Buy |
20.00 |
1,000 |
20,000 |
62,908 |
| Li Nan (LN) | Director |
May 11 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| Chu Shelley | Director |
May 11 '26 |
Buy |
18.00 |
11,111 |
199,998 |
11,111 |
1.27%
1.43%
자본화:
|
볼륨(24시간):